Experienced in Myelodysplastic Syndrome (MDS)

Dr. Thomas C. Anderson

Oncology
1615 Hospital Pkwy, Suite 300, 
Bedford, TX 
Experienced in Myelodysplastic Syndrome (MDS)
1615 Hospital Pkwy, Suite 300, 
Bedford, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Thomas Anderson is an Oncologist in Bedford, Texas. Dr. Anderson is rated as an Experienced provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). His top areas of expertise are Colorectal Cancer, Lynch Syndrome, Familial Colorectal Cancer, and Breast Cancer.

His clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO

Locations

1615 Hospital Pkwy, Suite 300, Bedford, TX 76022

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Enrollment Status: Terminated
Publish Date: March 23, 2022
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: November 24, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
View 5 Less Clinical Trials
Similar Doctors
Elite in Myelodysplastic Syndrome (MDS)
Dr. Yazan F. Madanat
Hematology Oncology | Hematology | Oncology
Elite in Myelodysplastic Syndrome (MDS)
Dr. Yazan F. Madanat
Hematology Oncology | Hematology | Oncology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (16.5 miles away)
214-645-0624
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Yazan Madanat is a Hematologist Oncology specialist and a Hematologist in Dallas, Texas. Dr. Madanat is rated as an Elite provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Distinguished in Myelodysplastic Syndrome (MDS)
Dr. Stephen S. Chung
Hematology Oncology | Oncology | Transplant Surgery
Distinguished in Myelodysplastic Syndrome (MDS)
Dr. Stephen S. Chung
Hematology Oncology | Oncology | Transplant Surgery

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, 
Dallas, TX 
 (16.1 miles away)
214-633-5555
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Chung is a Hematologist Oncology specialist and an Oncologist in Dallas, Texas. Dr. Chung is rated as a Distinguished provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). His top areas of expertise are Acute Myeloid Leukemia (AML), Hairy Cell Leukemia (HCL), Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Distinguished in Myelodysplastic Syndrome (MDS)
Dr. Robert B. Berryman
Oncology
Distinguished in Myelodysplastic Syndrome (MDS)
Dr. Robert B. Berryman
Oncology

Texas Oncology, P.A.

3410 Worth Street, Suite 300, 
Dallas, TX 
 (20.4 miles away)
972-449-0540
Experience:
32+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Berryman is an Oncologist in Dallas, Texas. Dr. Berryman has been practicing medicine for over 32 years and is rated as a Distinguished provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Anderson's expertise for a condition
ConditionClose
        View All 23 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile